A relação entre Doenças Hepáticas Esteatóticas e Risco Cardiovascular: Uma Revisão Narrativa

Abstract

This article reviews the evidence linking non-alcoholic fatty liver disease (NAFLD) and its variants, such as metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), to an increased risk of cardiovascular diseases (CVD). The methodology involved a comprehensive search of the PubMed database, focusing on relevant clinical studies and reviews. The results show that NAFLD, especially in its more advanced form, MASH, is strongly associated with a higher risk of CVD, surpassing other liver conditions. The studies identified a significant genetic interconnection between liver and cardiovascular diseases, while others revealed that patients with MASH have a higher incidence of CVD, confirming the high prevalence of MASLD in the Korean population and its impact on cardiovascular risk. Additionally, they highlighted the importance of the new SLD nomenclature to better reflect the underlying pathophysiology and associated risks. In conclusion, the effective management of cardiometabolic risk factors in patients with steatotic liver diseases is crucial to reducing mortality and improving health outcomes, underscoring the need for ongoing research to understand causal relationships and develop appropriate therapeutic interventions.